MedTrace Logo

Cerebrolysin and Neurodevelopment in Preterm Infants

NCT03506841 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-03-15

No results posted yet for this study

Summary

The overall aim of the study is to assess the effect of Cerebrolysin on physical and mental development of preterm infants by Denver Scale II at different ages of 5, 7 and 12 months

Conditions

  • Infant Development
  • Cerebral Palsy
  • Preterm Infant

Interventions

DRUG

Cerebrolysin

Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).

Sponsors & Collaborators

  • Mansoura University Children Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
5 Months
Max Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03506841 on ClinicalTrials.gov